Professor Nicola Dalbeth

MBChB MD FRACP

Biography

Nicola Dalbeth is an academic rheumatologist who leads a clinical and laboratory programme of research in gout, an inflammatory arthritis of major significance to Aotearoa New Zealand.  Her work focuses on understanding the impact and mechanisms of disease in gout. 

She has been lead investigator in both commercial and investigator-initiated clinical trials in gout.  She is a founding member of the Counties Manukau District Health Board Māori Gout Action Group. She chairs the Atlas of Healthcare Variation Gout Expert Advisory Group, and Australia and New Zealand Gout Special Interest Forum. She was the Lead Clinical Advisor for the Gout Clinical Pathways (Greater Auckland Integrated Healthcare Network) and the national bpac Gout Treatment Guidelines.  She has served as an Expert Panel member on the American College of Rheumatology Gout Management Guidelines, and is a steering committee member for the OMERACT gout working group and the ACR/EULAR gout classification project.

Research | Current

Clinical research includes clinical trials, imaging studies (using plain radiographs, MRI and three-dimensional CT modeling) to analyze joint damage, studies to investigate the functional impact of gout, and validation of outcome measures in gout.  The laboratory work in the Auckland Bone and Joint Research Laboratory involves investigating the cellular and molecular mechanisms of inflammation and joint damage in gout.

Selected publications and creative works (Research Outputs)

  • Weinman, J., Graham, S., Canfield, M., Kleinstäuber M, Perera, A. I., Dalbeth, N., & Petrie, K. J. (2018). The Intentional Non-Adherence Scale (INAS): Initial development and validation. Journal of psychosomatic research, 115, 110-116. 10.1016/j.jpsychores.2018.10.010
    Other University of Auckland co-authors: Maria Kleinstaeuber, Keith Petrie
  • Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., ... Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.. Rheumatology (Oxford, England). 10.1093/rheumatology/key237
    Other University of Auckland co-authors: Anne Horne
  • Dalbeth, N. (2018). ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol. Drug Metabolism and Pharmacokinetics, 33 (6), 241-242. 10.1016/j.dmpk.2018.09.002
  • Bursill, D., Taylor, W. J., Terkeltaub, R., & Dalbeth, N. (2018). The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. Seminars in arthritis and rheumatism, 48 (3), 456-461. 10.1016/j.semarthrit.2018.03.017
  • Rong, J., Pool, B., Zhu, M., Munro, J., Cornish, J., McCarthy, G. M., ... Poulsen, R. (2018). Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Phenotype Markers in Primary Human Chondrocytes by a Calcium/Calmodulin Kinase 2-Dependent Mechanism. Calcified tissue international10.1007/s00223-018-0494-1
    Other University of Auckland co-authors: Raewyn Poulsen, Jillian Cornish
  • Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., ... Dalbeth, N. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis research & therapy, 20 (1)10.1186/s13075-018-1755-0
    Other University of Auckland co-authors: Anne Horne
  • Dalbeth, N., Dowell, T., Gerard, C., Gow, P., Jackson, G., Shuker, C., & Te Karu, L. (2018). Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. The New Zealand medical journal, 131 (1485), 8-12.
  • Choi, H., Neogi, T., Stamp, L., Dalbeth, N., & Terkeltaub, R. (2018). New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis & rheumatology (Hoboken, N.J.), 70 (11), 1702-1709. 10.1002/art.40583

Identifiers

Contact details

Primary office location

M&HS BUILDING 502 - Bldg 502
Level 2, Room 201D
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand

Web links